MAGEA3 and metastatic malignant neoplasm: A phase I/II study of the treatment of metastatic cancer that expresses MAGE-A3, including BC, using lymphodepleting conditioning followed by the infusion of anti-MAGE-A3 HLA-A*01 restricted TCR-gene engineered lymphocytes, and aldesleukin was not concluded due to insufficient accrual; therefore, no statistical results could be concluded (NCT02153905).